"Everyone reads the abstract and then dismisses bisantrene as a dud when the actual paper says bisantrene beats doxorubicin..."
Going forward, any value in clarifying this for the greater audience? (apologies if this has already been done several times)
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220, page-98
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
-0.040(2.37%) |
Mkt cap ! $281.2M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.64 | $50.53K | 30.36K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 539 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 731 | 1 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |